UK spin‑out speeds up development and reduces animal testing More: Myomaker Bio unveils lab‑grown human muscle platform to transform drug testing Source: News
read moreAs Eli Lilly gets off to the races with the launch of its flagship oral GLP-1 Foundayo, the Indianapolis drugmaker—and at least one set of analysts—isn’t sweating what appears to be a slower-than-expected liftoff compared with Novo Nordisk’s rival Wegovy
read moreBristol Myers Squibb’s growth portfolio is offsetting declines in older products as planned, even as star heart drug Camzyos faces new competition. More: BMS 'well prepared' for Camzyos competition as revenue from new products overtakes legacy portfolio Source: fierce
read moreWhile Merck’s PAH treatment Winrevair continued its upward trajectory, another of its growth products, COPD medicine Ohtuvayre, took a step back in the first quarter. More: Merck's growth products Winrevair, Ohtuvayre trending in opposite directions Source: fierce
read more
Boehringer Ingelheim reports significant reductions in weight More: Survodutide delivers 16.6% weight loss in major phase 3 obesity trial Source: News
read moreAmarox, the U.K. unit of India’s Hetero Group, issued a voluntary recall of one batch of sertraline tablets in Britain after a patient found two different antidepressants packaged together. More: Amarox recalls batch of antidepressants in UK over packaging mix-up
read more© 1994 - 2026 B.M. Pharmaceuticals